Research Paper Volume 16, Issue 2 pp 1712—1732
Malignant cell receptor-ligand subtypes guide the prediction of prognosis and personalized immunotherapy of liver cancer
Figure 11. Validation of the risk score in HCC. (A) Survival analysis of TCGA-LIHC based on SRXN1 levels. (B) qRT-PCR images of tumor cell line (HEP3B, HCCLM3, HEPG2 and HUH7). SRXN1 levels were analyzed by qRT-PCR; **P < 0.01 versus liver cell line. (C) Representative images of Western blots of the liver cell line (THLE-2) and tumor cell line (HEP3B). SRXN1 levels were determined by Western blot (mean ± SEM; n = 5; **P < 0.001 versus THLE-2).